Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.45 |
| ▸ | HTR3B | O95264 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4236997 | 0.99 | HTR2A (0.54) | HTR2AGRM2HSD11B1CNR2NPC1 | |
| Trifluoroacetic Acid SCHEMBL29579487 | 0.91 | HTR2A (0.51) | HTR2AGRM2HSD11B1CNR2NPC1 | |
| Trifluoroacetic Acid SCHEMBL22118447 | 0.91 | HTR2A (0.51) | HTR2AGRM2HSD11B1CNR2NPC1 | |
| SCHEMBL22118493 | 0.88 | HTR2A (0.44) | HTR2AGRM2HSD11B1HTR3EHTR3B | |
| SCHEMBL13701309 | 0.86 | HTR2A (0.54) | HTR2AGRM2HSD11B1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL15566023 | 0.85 | HTR2C (0.53) | HSD11B1ALDH1A1LMNAHTR3EHTR3B | |
| SCHEMBL5968538 | 0.85 | HTR2A (0.43) | HTR2AGRM2HSD11B1HTR3EHTR3B | |
| SCHEMBL14420434 | 0.83 | MEN1 (0.44) | HTR2AGRM2HSD11B1CNR2NPC1 | |
| SCHEMBL4232496 | 0.80 | HSD11B1 (0.64) | HTR2AGRM2HSD11B1ALDH1A1LMNA | |
| SCHEMBL13701285 | 0.78 | HTR2A (0.58) | HTR2AGRM2HSD11B1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106272-A1 | Deuterated Forms And Derivatives Of Volinanserin | TERRAN BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| WO-2020132461-A1 | DEUTERATED FORMS AND DERIVATIVES OF VOLINANSERIN | CONCERT PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| CN-101412693-A | 4-[1-hydroxy-1-(2,3-dimethoxyphenyl)methyl]piperidine and method for preparing corresponding piperidine thereby | AVENTIS PHARMA INC (US) | 2009-04-22 | — | — | CN | disclosed |
| CN-101333184-A | Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4 piperidinemethanol | AVENTIS PHARMA INC (US) | 2008-12-31 | — | — | CN | disclosed |
| CN-100436415-C | Process for the preparation of -alpha- (2, 3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl ] -4-piperidinemethanol | HOECHST PHARMACEUTICAL INC (US) | 2008-11-26 | — | — | CN | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1736469-A2 | Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol | Aventis Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1734037-A2 | Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol\ | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261341-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050010051-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040210061-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. | 2004-10-21 | — | — | US | disclosed |
| US-6713627-B2 | FOR RECEPTOR ANTAGONISTS IN TREATMENT OF SCHIZOLPHRENIA, ANXIETY, VARIANT ANGINA, ANOREXIA VERVOSA, RAYNAUD'S PHENOMENON, INTERMITTENT CLAUDICATION, CORONARY OR PERIPHERAL VASOSPASMS, FIBROMYALGIA, CARDIAC ARRHYTHMIA'S, AND THROMBOSIS | AVENTIS PHARMACEUTICALS INC. | 2004-03-30 | — | — | US | disclosed |
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTISUB II INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| CN-1300280-A | Process for the preparation of -alpha- (2, 3-dimethoxyphenyl) -1- [ 2- (4-fluorophenyl) ethyl ] -4-piperidinemethanol | HOECHST PHARMA (US) | 2001-06-20 | — | — | CN | disclosed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CBR1 | HTR2A 1865/4885GRM2 715/4885HSD11B1 749/4885 |
| US-20050261341-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, CYP1A1, ADRM1 | HTR2A 1477/4885GRM2 781/4885HSD11B1 728/4885 |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | HTR2A 1477/4885GRM2 781/4885HSD11B1 728/4885 |
| US-20220106272-A1 | Deuterated Forms And Derivatives Of Volinanserin | DRD2, HTR3A, COMT | HTR2A 16/4885GRM2 848/4885HSD11B1 186/4885 |
| US-20040210061-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CYP1A1 | HTR2A 1662/4885GRM2 695/4885HSD11B1 693/4885 |
| US-20050010051-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, CYP1A1, ADRM1 | HTR2A 1477/4885GRM2 781/4885HSD11B1 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.